Cleared Traditional

K924654 - FIRST METATARSOPHALANGEAL JOINT MOTION SPLINT (FDA 510(k) Clearance)

Class I Physical Medicine device.

K924654 · Sutter Corp. · Physical Medicine device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1993
Decision
160d
Days
Class 1
Risk

K924654 is an FDA 510(k) clearance for the FIRST METATARSOPHALANGEAL JOINT MOTION SPLINT. Classified as Exerciser, Powered (product code BXB), Class I - General Controls.

Submitted by Sutter Corp. (San Diego, US). The FDA issued a Cleared decision on February 22, 1993 after a review of 160 days - an extended review cycle.

This device falls under the Physical Medicine FDA review panel, regulated under 21 CFR 890.5380 - the FDA physical medicine device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Physical Medicine review framework, consistent with the majority of Class II 510(k) submissions.

View all Sutter Corp. devices

Submission Details

510(k) Number K924654 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 15, 1992
Decision Date February 22, 1993
Days to Decision 160 days
Submission Type Traditional
Review Panel Physical Medicine (PM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
45d slower than avg
Panel avg: 115d · This submission: 160d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code BXB Exerciser, Powered
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 890.5380
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.